Polyendocrine metabolic ovarian syndrome (PMOS) has been announced as the new name for a condition previously known as polycystic ovarian syndrome (PCOS), which impacts more than 170 million women worldwide, according to a study released by The Lancet.
PCOS was previously defined as a common hormonal disorder when inappropriate amounts of androgen levels – or the concentration of male sex hormones – lead to irregular menstrual periods, abnormal ovulation, infertility, excessive body hair and acne, and cysts in the ovaries, according to The World Health Organization (WHO).
However, the study stated the name is inaccurate, as it creates misleading references to ovarian cysts and inaccurately reflects the diverse features of the condition. The name was said to have contributed to “delayed diagnosis, fragmented care, and stigma.”
The global study hosted workshops, surveys, and marketing and implementation analyses to create the new name that encompasses “scientific accuracy, clarity, stigma avoidance, cultural appropriateness, and implementation feasibility.”
“This change has global implications for healthcare systems, policy, and research, and for advancing understanding and treatment of the condition…Overall goals include greater awareness, enhanced diagnosis, improved care quality and patient satisfaction, and optimized outcomes across the broad features of the condition,” as stated in the study.
The new name transition will occur over a three-year period.
The name change reflects more answers for women. Although the current criteria suggest cysts, irregular periods, or signs of elevated testosterone, these do not always address a patient's concerns.
This name change now requires a more multi-systemic approach and support. Women globally are suffering from irregular cycles and painful periods, looking for answers.
This is a huge win in the women's health community because the approach will help patients. There are potentially other underlying causes. The potential to treat a more specific diagnosis can also possibly lead to access to and coverage of care. PMOS, polyendocrine metabolic ovarian syndrome, is not a misnomer and will allow patients to understand their care better.
About the Author
Dr. Arce is an obstetrician and gynecologist for Valley Medical Group.
